Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, discusses remaining questions from the phase 3 KEYNOTE-564 trial, which was presented at the 2021 ASCO Annual Meeting (LBA5). The study findings showed that adjuvant pembrolizumab (Keytruda) led to a significant reduction in the risk of disease recurrence or death versus placebo in patients with clear cell renal cell carcinoma. In the video, Figlin shares his expert observations on important questions that still remain, despite the positive results of the trial.
Enhancing the quality of bladder cancer care in the community setting
August 5th 2023Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.
BCAN session to highlight epigenetics and response to immunotherapy in bladder cancer
August 3rd 2023"I'm really optimistic that the session we are conducting will provide some recommendations [and] some ideas that will help us think about utilizing epigenetic therapies in a very evidence-based way," says Ania Woloszynska, PhD.
2 Clarke Drive
Cranbury, NJ 08512